Meeting
2023 ASCO Quality Care Symposium
Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine.
Authors
Garrett Rompelman
Dana-Farber Cancer Institute, Boston, MA
Garrett Rompelman, Jennifer Espiritu, Angela Chen, Jennifer A. Chan, Caroline Cole Block, Douglas Adam Rubinson, Joseph Jacobson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Patient Safety
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 396)
DOI
10.1200/OP.2023.19.11_suppl.396
Abstract #
396
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2016 Gastrointestinal Cancers Symposium
Germline pharmacogenomics in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
First Author: Moh'd M. Khushman
Poster
2013 ASCO Annual Meeting
Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer.
First Author: Gul Ahmed